Durable response to crizotinib in metastatic angiomatoid fibrous histiocytoma with EWSR1-CREB1 fusion and ALK overexpression

Ann Oncol. 2022 Aug;33(8):848-850. doi: 10.1016/j.annonc.2022.05.003. Epub 2022 May 12.
No abstract available

Publication types

  • Letter

MeSH terms

  • Crizotinib / therapeutic use
  • Cyclic AMP Response Element-Binding Protein / metabolism
  • Histiocytoma, Benign Fibrous*
  • Histiocytoma, Malignant Fibrous* / drug therapy
  • Histiocytoma, Malignant Fibrous* / genetics
  • Histiocytoma, Malignant Fibrous* / pathology
  • Humans
  • Oncogene Proteins, Fusion / genetics
  • Oncogene Proteins, Fusion / metabolism
  • RNA-Binding Protein EWS / genetics
  • Receptor Protein-Tyrosine Kinases

Substances

  • CREB1 protein, human
  • Cyclic AMP Response Element-Binding Protein
  • EWSR1 protein, human
  • EWSR1-CREB1 fusion protein, human
  • Oncogene Proteins, Fusion
  • RNA-Binding Protein EWS
  • Crizotinib
  • Receptor Protein-Tyrosine Kinases

Supplementary concepts

  • Histiocytoma, Angiomatoid Fibrous